Avisa Diagnostics Inc. (FOGCF) Stock

About Avisa Diagnostics Inc.

Avisa Diagnostics Inc. is a medical device company currently in its clinical development phase. The company is advancing the Avisa BreathTest, an innovative drug-device biomarker platform. This technology enables the exceptionally rapid identification and quantitative monitoring of virulent bacterial pathogens, activated when patients inhale or ingest its proprietary diagnostic compounds. Avisa Diagnostics has successfully established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis, and community-acquired pneumonia. Currently, the firm is concentrating its efforts on pivotal trials addressing Post-COVID-19 bronchiectasis and ventilator-associated pneumonia. Avisa Diagnostics Inc. is headquartered in Santa Fe, New Mexico.

Avisa Diagnostics Inc. (FOGCF) stock trades at $0.00 with a market capitalization of $97176. The stock is valued at a price-to-earnings (P/E) ratio of -0.23, price-to-book of -0.32, price-to-sales of 0.32. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Avisa Diagnostics Inc. generates a return on equity (ROE) of 100.00% — well above the market average, a sign of a high-quality business, return on capital employed of 187.73%, an operating margin of -251.59%, a net profit margin of -263.83%.

Official website: www.avisadx.com